A new survey report from the International Foundation of Employee Benefit Plans reveals results from a group of Canadian employers regarding considerations and coverage for glucagon-like peptide-1 (GLP-1) drugs, which have historically been used to treat diabetes and are increasingly being used to treat obesity
Most antibodies against the GLP-1 receptor are not considered to be highly specific (11), and there remains substantial controversy as to the precise expression of the GLP-1 receptor at the protein level in the kidney
Furthermore, cost and access can be barriers
Can I still file an Ozempic lawsuit if I stopped taking Ozempic
More potent medicines, such as semaglutide, tirzepatide, and liraglutide, may have superior anti-inflammatory effects
Medication is billed separately by official brand partners